Developing countries gain access to low-cost HIV prevention drug lenacapavir

Developing countries will receive a breakthrough HIV prevention drug, lenacapavir, for $40 per patient annually through agreements with pharmaceutical companies. Philanthropic organizations brokered the deals, aiming to increase access to the long-acting injectable medication in lower-income nations. This marks a significant step in global HIV prevention efforts. Lenacapavir offers a new prevention option, administered every six months, potentially transforming how HIV is managed and prevented worldwide.